Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymphoseek vs Albumin Nanocolloid for Sentinel Lymph Node Mapping in Cancer
NCT04261179Phase 4Unknown
- Start
- Mar 2020
- Primary completion
- Feb 2021
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of technetium tc 99m tilmanocept in head and neck cancer (HNC), melanoma and breast cancer. Primary endpoint: Proportion of lymph nodes identified by 99mTc-tilmanocept vs nanocolloidal human serum albumin at 48 hours. Status: unknown.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
head and neck cancer (HNC)melanomabreast cancer
Beyond the preview
Go deeper on NCT04261179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261179.